MRMarc Romana

Marc Romana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marc Romana has a total of 578 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Activation of Platelet Caspase‐1 and P‐Selectin Over‐Expression in Sickle Cell Disease Patients: An Involvement of NLRP3 Inflammasome?

    by Livia Claude, Frédéric Martino, Lydiane Mordier, Doris Célanie, Emmanuelle Bernit, Maryse Etienne‐Julan, Benoît Tressières, Marc Romana, Véronique Baccini

    Sickle cell disease (SCD) is characterized by hemolytic anaemia, painful vaso‐occlusive crises, and chronic inflammation resulting partly from platelet activation. It has been shown that platelets express the nucleotide‐binding domain leucine‐rich repeat containing protein 3 (NLRP3) and the apoptosis‐associated speck‐like protein containing a CARD (ASC), forming the NLRP3 inflammasome, which controls activation of caspase‐1 and cleavage of interleukin‐1β (IL‐1β). Bruton tyrosine kinase (BTK), known to activate the NLRP3 inflammasome, is also expressed in platelets. In SCD, platelets are activated and can secrete increased quantities of IL‐1β, suggesting a possible activation of the NLRP3 inflammasome. Here, we assessed platelet P‐selectin expression, caspase‐1 activation, platelet–neutrophil aggregate formations by flow cytometry and BTK phosphorylation by Western blot in a cohort of 81 adult SCD patients at steady state condition (34 SC and 47 SS patients). We showed an increase in platelet activation in sickle patients and a high level of platelet–neutrophil aggregate in SS patients compared to healthy subjects (17 AA). We also demonstrated platelet caspase‐1 activation in SCD patients and obtained data suggesting for the first time NLRP3 inflammasome activation in SC patients. Further studies are needed to understand the mechanism of caspase‐1 activation and evaluate the potential therapeutic efficiency of Ibrutinib, a BTK inhibitor.

  • Open Access

    Genetic, Clinical, and Biological Risk Factors Associated with Optic Nerve Thinning in Sickle Cell Disease.

    by Aliénor Vienne-Jumeau, Mhedi Siab, Marc Romana, Erika Laurent, Maryse Etienne-Julan, Philippe Connes, Laurence Beral

    Objectives To determine whether adults with sickle cell disease (SCD) without glaucoma exhibit subclinical optic neuropathy (ON) on optical coherence tomography (OCT) and to identify genetic, clinical, and biologic correlates of optic nerve thinning. Methods Monocentric, retrospective cross-sectional study of 185 eyes from 96 adults with SCD (116 eyes/59 HbSS; 69 eyes/37 HbSC) and 40 eyes from 20 controls. Spectral-domain OCT measured Bruch’s membrane opening–minimum rim width (BMO-MRW), peripapillary retinal nerve fiber layer (RNFL), and macular ganglion cell complex (GCC). ON was defined as concordant thinning across all three parameters. Patient-clustered models with Holm adjustment compared groups; multivariable clustered logistic regression identified risk factors. Results Compared with controls, SCD eyes showed thinner BMO-MRW, RNFL, and GCC (all p < 0.001). Within SCD, HbSC exhibited greater thinning than HbSS, especially in temporal and superonasal BMO-MRW sectors and RNFL average, inferotemporal, and superotemporal sectors. Proliferative SCR showed more pronounced loss than non-proliferative disease, including lower BMO-MRW, temporal RNFL thinning, and global GCC reduction. Hemoglobin correlated positively with BMO-MRW in HbSS (ρ = 0.41, p = 0.001), hematocrit tended toward a negative association with RNFL in HbSC (ρ=−0.29, p = 0.06), and reticulocytes were inversely associated with GCC in HbSS (ρ=−0.25, p = 0.038) and HbSC (ρ=−0.31, p = 0.038). Older age, recent acute chest syndrome, and ≥ 1 vaso-occlusive crisis within 2 years independently increased ON odds, whereas higher hemoglobin was protective. Conclusions Adults with SCD show OCT-detectable subclinical ON linked to genotype, retinopathy stage, anemia severity, and vaso-occlusive burden; combined BMO-MRW, RNFL, and GCC may aid risk-stratified surveillance.

  • The neutrophil antigen 3a/b polymorphism in SLC44A2 unexpectedly encodes the Csa/Csb red cell antigens

    by Romain Duval, Alissa Soudry, Jonathan De Oliveira Rios, Sarah Liane Linguet, Miguel Taillepierre, Graziella Matesic, Alexandre Raneri, Guy Laiguillon, Emilie Le Toriellec, Emilie-Fleur Gautier, et al.

    The Csa blood group antigen was identified >50 years ago, but its genetic basis has yet to be elucidated. All our recent genomic investigation has failed to resolve the genetic basis of this enigmatic antigen. By investigating the association of the human neutrophil antigen (HNA)-3a/b polymorphism (rs2288904-G/A) in SLC44A2 with clinical features of sickle cell disease, we incidentally discovered that rare subjects with the homozygous HNA-3b/b genotype also carry the uncommon Cs(a–) phenotype. We genotyped this single-nucleotide polymorphism in a cohort of 25 Cs(a–) subjects and found that all of them showed an HNA-3b/b genotype. This result suggests that the high-prevalence allele with rs2288904 (HNA-3a; 455G) encoding Arg152 encodes the high-prevalence Csa. Accordingly, anti-Csa does not react with solute carrier (SLC)44A2null red blood cells (RBCs), SLC44A2 knockout K562 cells, and K562 cells expressing HNA-3b, confirming that the Csa and Csb antigens are carried on this protein. Furthermore, mass spectrometry analysis of SLC44A2 from neutrophils and RBCs, along with serological investigation, showed that, despite HNA-3a and Csa having the same genetic basis, anti–HNA-3a and anti-Csa recognize different epitopes on the SLC44A2 protein. Overall, our data resolve the genetic bases of the Cs(a–) and Cs(b–) blood phenotypes, with new insights on the anti–HNA-3a specificity.


  • Open Access

    Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study

    by Amélie Rollé, Elsa Vidal, Pierre Laguette, Yohann Garnier, Delphine Delta, Frédéric Martino, Patrick Portecop, Maryse Etienne-Julan, Pascale Piednoir, Audrey De Jong, et al.

    Background and Objectives: Pain management poses a significant challenge for patients experiencing vaso-occlusive crisis (VOC) in sickle cell disease (SCD). While opioid therapy is highly effective, its efficacy can be impeded by undesirable side effects. Local regional anesthesia (LRA), involving the deposition of a perineural anesthetic, provides a nociceptive blockade, local vasodilation and reduces the inflammatory response. However, the effectiveness of this therapeutic approach for VOC in SCD patients has been rarely reported up to now. The objective of this study was to assess the effectiveness of a single-shot local regional anesthesia (LRA) in reducing pain and consequently enhancing the management of severe vaso-occlusive crisis (VOC) in adults with sickle cell disease (SCD) unresponsive to conventional analgesic therapy. Materials and Methods: We first collected consecutive episodes of VOC in critical care (ICU and emergency room) for six months in 2022 in a French University hospital with a large population of sickle cell patients in the West Indies population. We also performed a systematic review of the use of LRA in SCD. The primary outcome was defined using a numeric pain score (NPS) and/or percentage of change in opioid use. Results: We enrolled nine SCD adults (28 years old, 4 females) for ten episodes of VOC in whom LRA was used for pain management. Opioid reduction within the first 24 h post block was −75% (50 to 96%). Similarly, the NPS decreased from 9/10 pre-block to 0–1/10 post-block. Five studies, including one case series with three patients and four case reports, employed peripheral nerve blocks for regional anesthesia. In general, local regional anesthesia (LRA) exhibited a reduction in pain and symptoms, along with a decrease in opioid consumption post-procedure. Conclusions: LRA improves pain scores, reduces opioid consumption in SCD patients with refractory pain, and may mitigate opioid-related side effects while facilitating the transition to oral analgesics. Furthermore, LRA is a safe and effective procedure.


  • Open Access

    Association of haemolysis markers, blood viscosity and microcirculation function with organ damage in sickle cell disease in sub‐Saharan Africa (the BIOCADRE study)

    by Brigitte Ranque, Mor Diaw, Abdoul Karim Dembele, Claudine Lapoumeroulie, Lucile Offredo, Oumar Tessougue, Serigne Mourtalla Gueye, Dapa Diallo, Saliou Diop, Yves Colin‐Aronovicz, et al.

    Summary: Sickle cell anaemia (SCA) is a monogenic disease with a highly variable clinical course. We aimed to investigate associations between microvascular function, haemolysis markers, blood viscosity and various types of SCA‐related organ damage in a multicentric sub‐Saharan African cohort of patients with SCA. In a cross‐sectional study, we selected seven groups of adult patients with SS phenotype in Dakar and Bamako based on the following complications: leg ulcer, priapism, osteonecrosis, retinopathy, high tricuspid regurgitant jet velocity (TRV), macro‐albuminuria or none. Clinical assessment, echocardiography, peripheral arterial tonometry, laboratory tests and blood viscosity measurement were performed. We explored statistical associations between the biological parameters and the six studied complications. Among 235 patients, 58 had high TRV, 46 osteonecrosis, 43 priapism, 33 leg ulcers, 31 retinopathy and 22 macroalbuminuria, whereas 36 had none of these complications. Multiple correspondence analysis revealed no cluster of complications. Lactate dehydrogenase levels were associated with high TRV, and blood viscosity was associated with retinopathy and the absence of macroalbuminuria. Despite extensive phenotyping of patients, no specific pattern of SCA‐related complications was identified. New biomarkers are needed to predict SCA clinical expression to adapt patient management, especially in Africa, where healthcare resources are scarce.


  • Open Access

    Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib

    by Livia Claude, Frédéric Martino, Patricia Hermand, Bassel Chahim, Pierre‐Marie Roger, Marie de Bourayne, Yohann Garnier, Benoit Tressieres, Yves Colin, Caroline Le Van Kim, et al.


  • Open Access

    Erythrocyte type 1 equilibrative nucleoside transporter expression in sickle cell disease and sickle cell trait

    by Bérengère Koehl, Livia Claude, Karen Reminy, Vanessa Tarer, Véronique Baccini, Marc Romana, Yves Colin‐Aronovicz, Vijaya L. Damaraju, Michael Sawyer, Thierry Peyrard, et al.

    Summary: Hypoxia‐mediated red blood cell (RBC) sickling is central to the pathophysiology of sickle cell disease (SCD). The signalling nucleoside adenosine is thought to play a significant role in this process. This study investigated expression of the erythrocyte type 1 equilibrative nucleoside transporter (ENT1), a key regulator of plasma adenosine, in adult patients with SCD and carriers of sickle cell trait (SCT). Relative quantitative expression analysis of erythrocyte ENT1 was carried out by Western blot and flow cytometry. Patients with SCD with steady state conditions, either with SS or SC genotype, untreated or under hydroxycarbamide (HC) treatment, exhibited a relatively high variability of erythrocyte ENT1, but with levels not significantly different from normal controls. Most strikingly, expression of erythrocyte ENT1 was found to be significantly decreased in patients with SCD undergoing painful vaso‐occlusive episode and, unexpectedly, also in healthy SCT carriers. Promoting hypoxia‐induced adenosine signalling, the reduced expression of erythrocyte ENT1 might contribute to the pathophysiology of SCD and to the susceptibility of SCT individuals to altitude hypoxia or exercise to exhaustion.


  • Open Access

    Extracellular Vesicles in Sickle Cell Disease: A Promising Tool

    by Yann Lamarre, Elie Nader, Philippe Connes, Marc Romana, Yohann Garnier

    Sickle cell disease (SCD) is the most common hemoglobinopathy worldwide. It is characterized by an impairment of shear stress-mediated vasodilation, a pro-coagulant, and a pro-adhesive state orchestrated among others by the depletion of the vasodilator nitric oxide, by the increased phosphatidylserine exposure and tissue factor expression, and by the increased interactions of erythrocytes with endothelial cells that mediate the overexpression of adhesion molecules such as VCAM-1, respectively. Extracellular vesicles (EVs) have been shown to be novel actors involved in SCD pathophysiological processes. Medium-sized EVs, also called microparticles, which exhibit increased plasma levels in this pathology, were shown to induce the activation of endothelial cells, thereby increasing neutrophil adhesion, a key process potentially leading to the main complication associated with SCD, vaso-occlusive crises (VOCs). Small-sized EVs, also named exosomes, which have also been reported to be overrepresented in SCD, were shown to potentiate interactions between erythrocytes and platelets, and to trigger endothelial monolayer disruption, two processes also known to favor the occurrence of VOCs. In this review we provide an overview of the current knowledge about EVs concentration and role in SCD.


  • Open Access

    P-025: ABNORMAL MITOCHONDRIA RETENTION IN MATURE RED BLOOD CELLS OCCURS NOT ONLY IN SS BUT ALSO SC PATIENTS AND IS ASSOCIATED WITH HEMOLYTIC MARKERS

    by Romana M., Hardy-Dessources M., Ravion S., Garnier Y., Reininger L., Tarer V., Tressière B., Bernit E., LE VAN Kim C., Baccini V., et al.

  • Proteomic analysis of neutrophils from patients with COVID‐19

    by Marc Romana, Marjorie Leduc, Patricia Hermand, Johanna Bruce, Emilie‐Fleur Gautier, Frédéric Martino, Yohann Garnier, Véronique Baccini, Caroline Le Van Kim